SEC Contract Filing

Filing Date: 2021-05-06

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>knsa-20210331xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge 9.10.0.88--><!--Created on: 5/6/2021 08:28:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.43%;padding-right:10.95%;position:relative;"><div style="margin-top:30pt;min-height:29.2pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;">Exhibit 10.1</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#cccccc;border-bottom-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-bottom:0pt;text-align:center;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;"><a name="_Hlk70764973"></a><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#cccccc;border-bottom-style:none;border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-bottom:0pt;text-align:center;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#cccccc;border-bottom-style:none;border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-bottom:0pt;text-align:center;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;"><a name="_Hlk70764981"></a><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">COMMERCIAL SUPPLY AGREEMENT</b></p><p style="background-color:#cccccc;border-bottom-style:none;border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-bottom:0pt;text-align:center;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#cccccc;border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">This Commercial Supply Agreement (including Exhibit 1 hereto, this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into as of February 26, 2021 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) by and between:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Kiniksa Pharmaceuticals (UK), Ltd.</b>,<b style="font-weight:bold;"> </b>a company incorporated under the laws of England and Wales having its registered office at Third Floor, 23 Old Bond Street, London W1S 4PZ, England (&#8220;<b style="font-weight:bold;">KINIKSA</b>&#8221;),</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">and</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Regeneron Pharmaceuticals, Inc.</b>, a company organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (together with its Affiliates &#8220;<b style="font-weight:bold;">REGENERON</b>&#8221;).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">With each of KINIKSA and REGENERON collectively referred to as the &#8220;<b style="font-weight:bold;">Parties</b>&#8221; and individually as a &#8220;<b style="font-weight:bold;">Party</b>&#8221;.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-fam